On March 14, 2023 AbCellera (Nasdaq: ABCL) reported two upcoming poster presentations on its T-cell engager platform at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023, to be held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19 (Press release, AbCellera, MAR 14, 2023, View Source [SID1234628733]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AbCellera will present the complete characterization of its panel of differentiated CD3-binding antibodies and demonstrate how it enables customized design of T-cell engagers for cancer targets. Additionally, AbCellera will present data on the discovery and characterization of antibodies against MAGE-A4, a validated peptide-MHC (pMHC) target for cancer treatment. Together, these two presentations illustrate how AbCellera’s CD3 panel integrates with its antibody discovery and development engine to streamline T-cell engager development.

Details on AbCellera’s poster presentations at AACR (Free AACR Whitepaper) are as follows:

Title: Identifying T-cell engagers with optimal potency and cytokine-release profiles with a diverse panel of CD3-binding antibodies
Abstract Number: 1886
Date and Time: Monday, April 17 from 9:00 a.m. to 12:30 p.m. ET

Title: Breaking barriers to access intracellular targets with T-cell engagers: Discovery of diverse, developable, and ultra-specific antibodies against a MAGE-A4 pMHC
Abstract Number: 1891
Date and Time: Monday, April 17 from 9:00 a.m. to 12:30 p.m. ET